Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Adding Nubeqa to Therapy May Reduce PSA Levels in Metastatic Hormone-Sensitive Prostate Cancer
May 1st 2023Men with metastatic hormone-sensitive prostate cancer treated with Nubeqa, androgen-deprivation therapy and docetaxel had reductions in PSA levels that were associated with improved overall survival and a prolonged time to PSA progression.
Read More
Educated Patient® Breast Cancer Summit at MBCC HER2-Positive Disease Panel: March 4, 2023
March 2nd 2023Watch Dr. Naomi Dempsey, Dr. Ana Sandoval Leon, Dr. Rupesh Kotecha and Ricki Fairley answer questions about HER2-positive disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.
Read More
Educated Patient® Multiple Myeloma Summit Treating Myeloma Long-Term Panel: November 13, 2022
December 6th 2022Watch Valarie Traynham, of the HealthTree Foundation, discuss the long-term journey of the disease and disparities still seen during the CURE® Educated Patient® Multiple Myeloma Summit.
Read More
‘Planning Your Next Shot’ In the Prostate Cancer Continuum With Patient-Physician Communication
October 6th 2022As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Tony Crispino about the importance of patient-physician communication in prostate cancer.
Read More